Vyant Bio (VYNT) Stock Analysis

What Vyant Bio does

Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.

Key metrics

ETFs linked to VYNT

Broad-market and Healthcare sector ETFs an investor holding Vyant Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VYNT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Vyant Bio?

Vyant Bio trades under the ticker VYNT on NASDAQ.

Which exchange is VYNT listed on?

VYNT is listed on NASDAQ.

What sector does Vyant Bio operate in?

Vyant Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VYNT in a portfolio?

PortView shows VYNT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.